Healthcare

Vitasora Health Limited (ASX:VHL) provides technology-enabled connected care services, combining remote monitoring devices, clinical support and digital care management for people with chronic conditions. In 2026, the company focused on deploying its vCare platform, expanding patient enrolments and integrating its respiratory monitoring technology with …

The Canview platform sits within Vitura’s regulated healthcare distribution activities, supporting interactions between relevant healthcare providers, pharmacies and suppliers. Such systems can organise product ordering and related administrative tasks, but they do not replace the legal responsibilities of authorised prescribers or pharmacists. For Vitura …

Nanosonics Limited (ASX:NAN) develops infection prevention technologies for reprocessing reusable medical equipment, including its trophon ultrasound probe disinfection systems and CORIS endoscope cleaning platform. Its FY26 results, released in August 2026, showed a growing global trophon installed base alongside expenditure associated with developing and …

In an announcement dated 5 August 2026, Neuren Pharmaceuticals Limited (ASX:NEU) reported DAYBUE net sales of US$125 million for Q2 2026. The figure was 30% higher than Q2 2025 and 24% above Q1 2026. The company attributed the quarterly increase largely to patient volume, …

Noxopharm Limited (ASX:NOX) is an Australian clinical-stage biotechnology company developing treatments for inflammation, autoimmune disease and cancer. Its Sofra platform investigates synthetic oligonucleotides that regulate immune signalling, while its Chroma platform concentrates on oncology drug candidates. The company’s 2026 disclosures place SOF-SKN clinical preparations …

On 26 May 2026, NeuroScientific Biopharmaceuticals Limited (ASX:NSB) reported results from an Australian special-access program involving five patients with fistulising Crohn’s disease. The company said all five showed improvement and four achieved its defined clinical response, representing 80% of the small patient group. It …

Neurotech International Limited (ASX:NTI) is a clinical-stage biopharmaceutical company developing NTI164, an oral cannabinoid-based investigational therapy for paediatric neurological disorders. Its 2026 disclosures place autism spectrum disorder (ASD) at the centre of clinical development, alongside research into Rett syndrome and paediatric acute-onset neuropsychiatric syndrome …